HEC workshop on clinical research concludes.
The News Review:
- HEC workshop on clinical research concludes.
- BioAlliance Pharma Accelerates Its International Clinical Research…
- RadPharm Announces $10 million Series B Financing led by Siemens…
- A traffic cop for health research
- special report : science career issues and alternative jobs for…
- Growth of CT Scan Use May Lead to Significant Public Health Problem
HEC workshop on clinical research concludes.
Free with registration – PPI – Pakistan Press International – AccessMyLibrary.com – Nov 28, 2007
–>CPYRIGHT 2007 Asia Pulse Pty Ltd KARACHI November 28 (PPI) : National Core group in Life Sciences (NCGLS) of the Higher Education Commission (HEC) in collaboration with Bahria University Islamabad organized a two-day workshop on Clinical Research in Life Sciences and its industrial implications at HEC office Islamabad. The aim of this workshop was to improve. CPYRIGHT 2007 Asia Pulse Pty Ltd.
BioAlliance Pharma Accelerates Its International Clinical Research…
Genetic Engineering News – Genetic Engineering News (press release) – Nov 28, 2007
Thecompany is planning to submit market authorization applications in thefirst half of 2009 in Europe and in the United States subject toadditional regulatory requirements. Furthermore after successful completion of patient enrolment inthe pivotal phase III clinical trial performed with a view toregistering Loramyc(R) in the US the company is continuing to openadditional European centers for its phase III doxorubicin Transdrug(R)trial in primary liver cancer. “This successful international extension of our trials confirmsthe quality of BioAlliance Pharma’s Clinical Research and RegulatoryAffairs teams” commented Dominique Costantini President of theManagement Board. “With Acyclovir Lauriad(R) in the USA our objectiveis to be able to access 60% of the potential market that the productrepresents”. About BioAlliance Pharma BioAlliance Pharma SA is a specialty pharmaceutical companyfocused on the treatment of opportunistic infections in cancer andHIV. The company develops and commercializes innovative products whichaddress resistance issues. The company has launched its firstportfolio product (Loramyc(R)) in France which is currently in PhaseIII clinical development in oropharyngeal candidiasis in the USA.
RadPharm Announces $10 million Series B Financing led by Siemens…
Free with registration – PR Newswire – AccessMyLibrary.com – Nov 28, 2007
a leading provider of medical image review services for clinical research announced the completion of a $10 million Series B financing led by Siemens Venture Capital (”SVC”). Existing investors Ampersand Ventures Adams Street Partners and Tang Capital Management participated in the financing. “Siemens brings a wealth of expertise in medical imaging and clinical research and we are delighted to welcome them as an investor” explained Ronald A. Berg President and CE of RadPharm. Berg added “This financing marks another key milestone for RadPharm in.
A traffic cop for health research
Globe and Mail – Nov 28, 2007
Chartrand explains that the CIHR is divided into 13 “virtual institutes” to establish the agency’s priorities in health research and to ensure money flows to the right place. “There is an institute in gender health there’s an institute in aging on aboriginal health on cancer research and so on” he says. “The mandate is to look at all aspects of disease of prevention the social and economic factors and traditional clinical research. “It is a wide mandate. We try to tap into the excellence of all health research in this country. The first most important thing is the quality of that research. Peers in the same field as the applicants are brought in as volunteers to judge the quality of proposals Dr.
special report : science career issues and alternative jobs for…
Nature.com – Nature.com (subscription) – Nov 28, 2007
Indeed the challenges are many. Despite the success of the NIH’s interdisciplinary Specialized Programs of Research Excellence (SPRE) grants — started by the National Cancer Institute in 1992 — there have been pitfalls. SPRE grants have one director who oversees a minimum of four research projects each of which has two co-leaders: one for basic research and one for clinical research. The grants which target translational cancer research require a clinical trial at the end of five years. It’s been a tough target to meet. 5-million-a-year SPRE grant is divided up among all participants it works out to less than the average R01 grant which is typically $220000 a year.
Growth of CT Scan Use May Lead to Significant Public Health Problem
newswise.com – Nov 28, 2007
from the Center for Radiological Research at Columbia University Medical Center argue that the potential carcinogenic effects from using CT scans may be underestimated or overlooked. This is of particular concern because perhaps one-third of all CT scans performed in the United States may not be medically necessary the radiation researchers say. It is estimated that more than 62 million CT scans per year are currently given in the United States compared to three million 1980. Because CT scans result in a far larger radiation exposure compared with conventional plain-film X-ray this has resulted in a marked increase in the average personal radiation exposure in the United States which has about doubled since 1980 largely because of the increased CT usage. It used to be widely believed that all radiological examinations were essentially harmless because of the small amounts of radiation involved but Drs.
Written by admin on November 28th, 2007 with
no comments.
Read more articles on News.